Impacting Global Health Delivery Through Advocacy: The Case of Losartan
By: David J. Heller and Sandeep P. Kishore
Abstract
Highlights
- The WHO’s EML improves medicine access.
- Anyone can lobby to add a medicine to the EML, so we added losartan in 2017.
- Evidence now shows losartan is more impactful than previously realized.
- You too can use the EML to effect policy change—by adding to or amending it.
- Also, you can hold governments accountable to keep EML medicines on their shelves.
DOI: https://doi.org/10.1016/j.gheart.2018.11.001 | Journal eISSN: 2211-8179
Language: English
Published on: Mar 1, 2019
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2019 David J. Heller, Sandeep P. Kishore, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.